【摘要】 目的:研究静脉注射重组人脑利钠肽(rhBNP)治疗老年充血性心力衰竭患者的疗效。方法:118例老年充血性心力衰竭患者被随机分为:常规治疗组(56例),给予常规药物治疗;rhBNP组(n=62),以rhBNP 1.5μg/kg静脉注射后,再以0.0075μg/kg连续滴注;观察两组治疗前后超声心动图变化,血浆N末端脑利钠肽前体(NT-proBNP)浓度的变化以及出院后患者主要心血管事件的发生情况。结果:与治疗前比较,治疗5d后rhBNP组左室射血分数明显提高[(0.37±0.10)∶(0.44±0.09),P<0.05];两组血浆NT-proBNP水平均有明显下降[常规治疗组(7532.7±1005.6)pg/ml∶(7056.5±998.3)pg/ml,rhBNP组(7565.1±1102.3)pg/ml∶(6206.7±1137.9)pg/ml,P<0.05],且rhBNP治疗组下降更明显(P<0.05);两组患者治疗前后左心室舒张末期内径(LVEDd)无明显变化(P>0.05);在8个月的随访期内rhBNP组心脏不良事件少于常规治疗组(9.7%∶28.6%)。结论:重组人脑利钠肽是治疗老年充血性心力衰竭的有效药物。更多还原

【Abstract】 Objective:To study the therapeutic effects of intravenous injection of recombinant human brain natriuretic peptide(rhBNP) on congestive heart failure(CHF) in aged patients.Methods: A total of 118 aged patients with CHF were randomly divided into routine treatment group(n=56,received routine drug treatment) and rhBNP group(n=62,received rhBNP intravenous injection with 1.5μg/kg within 90s followed by 0.0075μg/kg·min iv drop for 48h).Changes of echocardiogram and plasma concentration of N terminal-proBNP(NT-proBNP) before and after treatment and incidence of main adverse cardiovascular events(MACE) post-discharge were observed and analyzed in the two groups.Results: Compared with before treatment,five days after treatment left ventricular ejection infraction significantly increased [(0.37±0.10) vs.(0.44±0.09),P<0.05] in rhBNP group.Plasma levels of NT-proBNP of the two groups significantly decreased [routine treatment group(7532.7±1005.6) pg/ml vs.(7056.5±998.3) pg/ml,rhBNP group(7565.1±1102.3) pg/ml vs.(6206.7±1137.9) pg/ml,P<0.05],and it′s more significant in rhBNP group(P<0.05).Left ventricular end-diastolic dimension(LVEDd) of the two groups showed no significant changes before and after treatment(P>0.05).During follow up period of eight months,rhBNP group had fewer cardiovascular events(9.7%) than routine treatment group(28.6%).Conclusion: Recombinant human brain natriuretic peptide is an effective drug for treatment of congestive heart failure in aged patients.更多还原